Maximo F. Nougues
Net Worth

Last updated:

What is Maximo F. Nougues net worth?

The estimated net worth of Mr. Maximo F. Nougues is at least $7,605,333 as of 2 Jul 2024. He owns shares worth $831,723 as insider, has earned $253,610 from insider trading and has received compensation worth at least $6,520,000 in Puma Biotechnology, Inc..

What is the salary of Maximo F. Nougues?

Mr. Maximo F. Nougues salary is $1,630,000 per year as Chief Financial Officer & Principal Accounting Officer in Puma Biotechnology, Inc..

How old is Maximo F. Nougues?

Mr. Maximo F. Nougues is 56 years old, born in 1969.

What stocks does Maximo F. Nougues currently own?

As insider, Mr. Maximo F. Nougues owns shares in one company:

Company Title Shares Price per share Total value
Puma Biotechnology, Inc. (PBYI) Chief Financial Officer & Principal Accounting Officer 166,678 $4.99 $831,723

What does Puma Biotechnology, Inc. do?

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

PBYI logo
PBYI
Puma Biotechnology, Inc.
$4.99

Maximo F. Nougues insider trading

Puma Biotechnology, Inc.

Mr. Maximo F. Nougues has made 28 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 5,295 units of PBYI stock worth $17,309 on 2 Jul 2024.

The largest trade he's ever made was exercising 15,682 units of PBYI stock on 3 Jan 2024. As of 2 Jul 2024 he still owns at least 166,678 units of PBYI stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 5,295 $3.27 $17,309
Sale
Common Stock 15,682 $4.49 $70,349
Sale
Common Stock 14,680 $3.31 $48,605
Sale
Common Stock 10,499 $4.18 $43,865
Sale
Common Stock 159 $4.5 $715
Sale
Common Stock 163 $2.25 $367
Sale
Common Stock 165 $2.34 $385
Sale
Common Stock 164 $2.59 $425
Sale
Common Stock 161 $2.89 $465
Sale
Common Stock 5,835 $2.63 $15,358
Sale
Common Stock 162 $1.92 $311
Sale
Common Stock 165 $2.34 $386
Sale
Common Stock 206 $3.08 $634
Sale
Common Stock 169 $2.26 $382
Sale
Common Stock 199 $2.48 $494
Sale
Common Stock 7,484 $3.19 $23,874
Sale
Common Stock 162 $2.95 $478
Sale
Common Stock 156 $5.67 $885
Sale
Common Stock 161 $6.2 $998
Sale
COMMON STOCK 155 $7.51 $1,164
Sale
COMMON STOCK 154 $7.54 $1,161
Sale
COMMON STOCK 155 N/A N/A
Sale
COMMON STOCK 152 N/A N/A
Sale
COMMON STOCK 152 $9.91 $1,506
Sale
COMMON STOCK 155 N/A N/A
Sale
COMMON STOCK 154 $10.14 $1,561
Sale
COMMON STOCK 179 N/A N/A
Sale
COMMON STOCK 2,145 $10.22 $21,930

Puma Biotechnology key executives

Puma Biotechnology, Inc. executives and other stock owners filed with the SEC:

  • Mr. Alan H. Auerbach (55) Founder, Chairman, Pres, Chief Executive Officer & Sec.
  • Mr. Douglas Hunt B.Sc., FRAPS (60) Senior Vice President of Regulatory Affairs, Medical Writing & Project Management
  • Mr. Jeffrey Jerome Ludwig (59) Chief Commercial Officer
  • Mr. Maximo F. Nougues (56) Chief Financial Officer & Principal Accounting Officer